{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:09:49Z","timestamp":1792588189406,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["2017J3E2W2_002"],"award-info":[{"award-number":["2017J3E2W2_002"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2019-23139"],"award-info":[{"award-number":["IG 2019-23139"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jhep.2021.07.029","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T15:19:20Z","timestamp":1628176760000},"page":"1440-1451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver"],"prefix":"10.1016","volume":"75","author":[{"given":"Raffaella Maria","family":"Gadaleta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/j.1460-2075.1991.tb07654.x","article-title":"FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern","volume":"10","author":"Partanen","year":"1991","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cytogfr.2005.01.008","article-title":"Structural basis for fibroblast growth factor receptor activation","volume":"16","author":"Mohammadi","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jhep.2021.07.029_bib3","doi-asserted-by":"crossref","first-page":"D165","DOI":"10.2741\/Klint","article-title":"Signal transduction by fibroblast growth factor receptors","volume":"4","author":"Klint","year":"1999","journal-title":"Front Biosci"},{"issue":"23","key":"10.1016\/j.jhep.2021.07.029_bib4","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0378-1119(92)90108-2","article-title":"Cloning, expression and tissue distribution of the gene encoding rat fibroblast growth factor receptor subtype 4","volume":"120","author":"Horlick","year":"1992","journal-title":"Gene"},{"issue":"7","key":"10.1016\/j.jhep.2021.07.029_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/002215549704500710","article-title":"Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues","volume":"45","author":"Hughes","year":"1997","journal-title":"J\u00a0Histochem Cytochem"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0960-9822(95)00102-3","article-title":"Functions of fibroblast growth factors and their receptors","volume":"5","author":"Wilkie","year":"1995","journal-title":"Curr Biol"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5009\/gnl17443","article-title":"Expression of fibroblast growth factor 21 and beta-Klotho regulates hepatic fibrosis through the nuclear factor-kappaB and c-Jun N-terminal kinase pathways","volume":"12","author":"Lee","year":"2018","journal-title":"Gut Liver"},{"key":"10.1016\/j.jhep.2021.07.029_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1101\/sqb.2011.76.010710","article-title":"Roles of FGF19 in liver metabolism","volume":"76","author":"Kir","year":"2011","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"10","key":"10.1016\/j.jhep.2021.07.029_bib12","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"37","key":"10.1016\/j.jhep.2021.07.029_bib13","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"37","key":"10.1016\/j.jhep.2021.07.029_bib14","doi-asserted-by":"crossref","first-page":"27277","DOI":"10.1074\/jbc.M704244200","article-title":"Liver-specific activities of FGF19 require Klotho beta","volume":"282","author":"Lin","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2174\/1566524014666140724095112","article-title":"Hepatocyte FRS2alpha is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity","volume":"14","author":"Wang","year":"2014","journal-title":"Curr Mol Med"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cmet.2014.05.020","article-title":"Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15\/19 signaling to repress bile acid synthesis","volume":"20","author":"Li","year":"2014","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.jhep.2021.07.029_bib18","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI23076","article-title":"Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho","volume":"115","author":"Ito","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib19","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1073\/pnas.0913986107","article-title":"Relevant use of Klotho in FGF19 subfamily signaling system in\u00a0vivo","volume":"107","author":"Tomiyama","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"10.1016\/j.jhep.2021.07.029_bib20","doi-asserted-by":"crossref","first-page":"15482","DOI":"10.1074\/jbc.275.20.15482","article-title":"Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4","volume":"275","author":"Yu","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"18","key":"10.1016\/j.jhep.2021.07.029_bib21","doi-asserted-by":"crossref","first-page":"17707","DOI":"10.1074\/jbc.M411771200","article-title":"Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids","volume":"280","author":"Yu","year":"2005","journal-title":"J\u00a0Biol Chem"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib22","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J\u00a0Lipid Res"},{"issue":"49","key":"10.1016\/j.jhep.2021.07.029_bib23","doi-asserted-by":"crossref","first-page":"41334","DOI":"10.1074\/jbc.M112.421834","article-title":"Nuclear receptors HNF4alpha and LRH-1 cooperate in regulating Cyp7a1 in\u00a0vivo","volume":"287","author":"Kir","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-2275(20)32068-X","article-title":"HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7alpha-hydroxylase gene (CYP7A1)","volume":"41","author":"Stroup","year":"2000","journal-title":"J\u00a0Lipid Res"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/me.2007-0565","article-title":"Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis","volume":"22","author":"Lee","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1210\/me.2015-1226","article-title":"FXR primes the liver for intestinal FGF15 signaling by transient induction of beta-Klotho","volume":"30","author":"Fu","year":"2016","journal-title":"Mol Endocrinol"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab"},{"issue":"6024","key":"10.1016\/j.jhep.2021.07.029_bib29","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib30","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib31","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"issue":"17","key":"10.1016\/j.jhep.2021.07.029_bib32","doi-asserted-by":"crossref","first-page":"11110","DOI":"10.1074\/jbc.M808747200","article-title":"FGF15\/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action","volume":"284","author":"Shin","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2021.07.029_bib33","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Sung","year":"2021","journal-title":"CA Canc J Clin"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver cancer cell of origin, molecular class, and effects on patient prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"issue":"10064","key":"10.1016\/j.jhep.2021.07.029_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"10126","key":"10.1016\/j.jhep.2021.07.029_bib36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"36","key":"10.1016\/j.jhep.2021.07.029_bib39","doi-asserted-by":"crossref","first-page":"57633","DOI":"10.18632\/oncotarget.9328","article-title":"Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival","volume":"7","author":"Tiong","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.jhep.2021.07.029_bib40","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1021\/acs.jproteome.5b00508","article-title":"Quantitative proteomic verification of membrane proteins as potential therapeutic targets located in the 11q13 amplicon in cancers","volume":"14","author":"Hoover","year":"2015","journal-title":"J\u00a0Proteome Res"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/1759-7714.12504","article-title":"FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas","volume":"8","author":"Zhang","year":"2017","journal-title":"Thorac Canc"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000439536","article-title":"FGFR4 is a potential predictive biomarker in oral and oropharyngeal squamous cell carcinoma","volume":"82","author":"Koole","year":"2015","journal-title":"Pathobiology"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010031","article-title":"Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies","volume":"8","author":"Lang","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib45","first-page":"133","article-title":"Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma","volume":"38","author":"Motoda","year":"2011","journal-title":"Int J Oncol"},{"issue":"9","key":"10.1016\/j.jhep.2021.07.029_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cells8091091","article-title":"Expression of FGFR1-4 in malignant pleural mesothelioma tissue and corresponding cell lines and its relationship to patient survival and FGFR inhibitor sensitivity","volume":"8","author":"Vlacic","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.jhep.2021.07.029_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2008.08.015","article-title":"Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention","volume":"50","author":"Ho","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000342405","article-title":"Emerging signaling pathways in hepatocellular carcinoma","volume":"1","author":"Moeini","year":"2012","journal-title":"Liver Cancer"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060536","article-title":"FGF19-FGFR4 signaling in hepatocellular carcinoma","volume":"8","author":"Raja","year":"2019","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib53","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.27198","article-title":"Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification","volume":"60","author":"Ahn","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052711","article-title":"Regulation of amphiregulin gene expression by beta-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system","volume":"7","author":"Latasa","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.07.029_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-12-56","article-title":"Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma","volume":"12","author":"Miura","year":"2012","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/hep.26402","article-title":"Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma","volume":"58","author":"Wang","year":"2013","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib57","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.tem.2017.10.007","article-title":"Mitogen-activated protein kinase regulation in hepatic metabolism","volume":"28","author":"Lawan","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib58","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/JME-15-0146","article-title":"Stress kinases in the modulation of metabolism and energy balance","volume":"55","author":"Manieri","year":"2015","journal-title":"J\u00a0Mol Endocrinol"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib59","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1172\/JCI76094","article-title":"Targeting cancer with kinase inhibitors","volume":"125","author":"Gross","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/cbir.1995.1086","article-title":"The epidermal growth factor","volume":"19","author":"Boonstra","year":"1995","journal-title":"Cell Biol Int"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib61","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","article-title":"Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC","volume":"130","author":"Calvisi","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib62","first-page":"1001","article-title":"Integrin-mediated signal transduction pathways","volume":"14","author":"Cary","year":"1999","journal-title":"Histol Histopathol"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0955-0674(03)00008-5","article-title":"Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells","volume":"15","author":"Stacey","year":"2003","journal-title":"Curr Opin Cell Biol"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib64","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Canc Res"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3748\/wjg.v7.i1.33","article-title":"Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance","volume":"7","author":"Feng","year":"2001","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib66","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccr.2009.12.048","article-title":"Hepatocyte IKKbeta\/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation","volume":"17","author":"He","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib67","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/hep.24486","article-title":"Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3","volume":"54","author":"Jiang","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.07.029_bib68","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2147\/OTT.S156198","article-title":"Clinicopathological significance and prognostic role of p-STAT3 in patients with hepatocellular carcinoma","volume":"11","author":"Liang","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib69","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib70","doi-asserted-by":"crossref","first-page":"13575","DOI":"10.18632\/oncotarget.6185","article-title":"FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3beta\/beta- catenin signaling cascade via FGFR4 activation","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.jhep.2021.07.029_bib72","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2021.07.029_bib73","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3892\/ijo.2016.3535","article-title":"Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma","volume":"49","author":"Ye","year":"2016","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib76","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A\u00a0mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib77","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Canc Res"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171185","article-title":"Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation","volume":"12","author":"Massafra","year":"2017","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.jhep.2021.07.029_bib79","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1158\/0008-5472.CAN-17-2039","article-title":"FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3beta-Nrf2 signaling","volume":"77","author":"Teng","year":"2017","journal-title":"Canc Res"},{"issue":"3-4","key":"10.1016\/j.jhep.2021.07.029_bib80","doi-asserted-by":"crossref","first-page":"125","DOI":"10.18632\/genesandcancer.101","article-title":"FGF19 functions as autocrine growth factor for hepatoblastoma","volume":"7","author":"Elzi","year":"2016","journal-title":"Genes Cancer"},{"issue":"31","key":"10.1016\/j.jhep.2021.07.029_bib81","doi-asserted-by":"crossref","first-page":"49091","DOI":"10.18632\/oncotarget.10077","article-title":"Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment","volume":"7","author":"Kaibori","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib82","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Canc Discov"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib83","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13402-017-0354-4","article-title":"Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report","volume":"41","author":"Gao","year":"2018","journal-title":"Cell Oncol (Dordr )"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib84","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic Messengers: fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat Metab"},{"issue":"18","key":"10.1016\/j.jhep.2021.07.029_bib85","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1042\/BCJ20180555","article-title":"Differential receptor selectivity of the FGF15\/FGF19 orthologues determines distinct metabolic activities in db\/db mice","volume":"475","author":"Hansen","year":"2018","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib86","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","article-title":"Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15","volume":"66","author":"Zhou","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2021.07.029_bib87","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1999.0485","article-title":"FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4","volume":"11","author":"Xie","year":"1999","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib88","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.jhep.2021.07.029_bib89","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1021\/acs.jmedchem.7b00360","article-title":"Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(me thylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors","volume":"60","author":"Brameld","year":"2017","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-16-0188","article-title":"ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4, inhibits the growth of FGF19-expressing hepatocellular carcinoma","volume":"16","author":"Futami","year":"2017","journal-title":"Mol Canc Ther"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib91","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","article-title":"A\u00a0phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer","volume":"12","author":"Michael","year":"2017","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib92","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10637-016-0416-x","article-title":"Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study","volume":"35","author":"Saka","year":"2017","journal-title":"Invest N Drugs"},{"issue":"20","key":"10.1016\/j.jhep.2021.07.029_bib93","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J\u00a0Med Chem"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib94","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Canc Discov"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib95","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.30481","article-title":"Infigratinib mediates vascular normalization, impairs metastasis, and improves chemotherapy in hepatocellular carcinoma","volume":"69","author":"Huynh","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib96","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10637-017-0514-4","article-title":"Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors","volume":"36","author":"Nishina","year":"2018","journal-title":"Invest N Drugs"},{"issue":"9","key":"10.1016\/j.jhep.2021.07.029_bib97","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib98","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/2159-8290.CD-15-0246","article-title":"Paralog-specific kinase inhibition of FGFR4: adding to the arsenal of anti-FGFR agents","volume":"5","author":"Packer","year":"2015","journal-title":"Canc Discov"},{"issue":"11","key":"10.1016\/j.jhep.2021.07.029_bib99","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/s12276-020-00524-4","article-title":"FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma","volume":"52","author":"Huynh","year":"2020","journal-title":"Exp Mol Med"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib100","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1535-7163.MCT-18-1291","article-title":"FGF401, A first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer","volume":"18","author":"Weiss","year":"2019","journal-title":"Mol Canc Ther"},{"issue":"24","key":"10.1016\/j.jhep.2021.07.029_bib101","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","article-title":"H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma","volume":"77","author":"Joshi","year":"2017","journal-title":"Canc Res"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib102","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Canc Discov"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib103","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/toxsci\/kfs011","article-title":"Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys","volume":"126","author":"Pai","year":"2012","journal-title":"Toxicol Sci"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib104","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/liv.12462","article-title":"Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations","volume":"34","author":"Mellor","year":"2014","journal-title":"Liver Int"},{"issue":"7518","key":"10.1016\/j.jhep.2021.07.029_bib105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature13438","article-title":"Proteogenomic characterization of human colon and rectal cancer","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.jhep.2021.07.029_bib106","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study","volume":"101","author":"Chang","year":"2009","journal-title":"J\u00a0Natl Canc Inst"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001313","article-title":"Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Kimer","year":"2012","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib108","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1016\/j.jhep.2021.07.029_bib109","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"issue":"39","key":"10.1016\/j.jhep.2021.07.029_bib110","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.3748\/wjg.v24.i39.4436","article-title":"Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer","volume":"24","author":"O'Rourke","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib111","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.dld.2009.09.002","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal","volume":"42","author":"Trevisani","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.jhep.2021.07.029_bib112","doi-asserted-by":"crossref","first-page":"G893","DOI":"10.1152\/ajpgi.00337.2013","article-title":"Fibroblast growth factor 15 deficiency impairs liver regeneration in mice","volume":"306","author":"Kong","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib113","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/gutjnl-2012-302945","article-title":"Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice","volume":"62","author":"Uriarte","year":"2013","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib114","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.dld.2017.08.023","article-title":"Fibroblast growth factor 15 deficiency increases susceptibility but does not improve repair to acetaminophen-induced liver injury in mice","volume":"50","author":"Huang","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib115","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/hep.25905","article-title":"Promotion of liver regeneration\/repair by farnesoid X receptor in both liver and intestine in mice","volume":"56","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhep.2021.07.029_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.480","article-title":"Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice","volume":"8","author":"Alvarez-Sola","year":"2017","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib117","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hep.27274","article-title":"Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation","volume":"61","author":"Degirolamo","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib118","first-page":"1237","article-title":"Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis","volume":"145","author":"Mauad","year":"1994","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib119","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.1038\/s41598-017-11549-7","article-title":"Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(-\/-) mice","volume":"7","author":"Cariello","year":"2017","journal-title":"Sci Rep"},{"issue":"4 Pt B","key":"10.1016\/j.jhep.2021.07.029_bib120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbadis.2017.06.025","article-title":"Bile acids, FGF15\/19 and liver regeneration: from mechanisms to clinical applications","volume":"1864","author":"Alvarez-Sola","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib121","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.gastro.2015.05.043","article-title":"Fibroblast growth factor signaling controls liver size in mice with humanized livers","volume":"149","author":"Naugler","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib122","first-page":"390","article-title":"Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome","volume":"41","author":"Barutcuoglu","year":"2011","journal-title":"Ann Clin Lab Sci"},{"issue":"7","key":"10.1016\/j.jhep.2021.07.029_bib123","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/dc12-2255","article-title":"A\u00a0role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass","volume":"36","author":"Gerhard","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jhep.2021.07.029_bib124","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1210\/jc.2016-1607","article-title":"Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes","volume":"101","author":"Sonne","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib125","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/00365510701854967","article-title":"Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test","volume":"68","author":"Stejskal","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients","volume":"39","author":"Gallego-Escuredo","year":"2015","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib127","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clnu.2016.04.027","article-title":"FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss","volume":"36","author":"Gomez-Ambrosi","year":"2017","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib128","doi-asserted-by":"crossref","first-page":"627","DOI":"10.33549\/physiolres.932099","article-title":"Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment","volume":"60","author":"Mraz","year":"2011","journal-title":"Physiol Res"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib129","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/2050640614527938","article-title":"Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals","volume":"2","author":"Renner","year":"2014","journal-title":"United Eur Gastroenterol J"},{"issue":"9","key":"10.1016\/j.jhep.2021.07.029_bib130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinbiochem.2012.03.019","article-title":"Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"45","author":"Eren","year":"2012","journal-title":"Clin Biochem"},{"issue":"10","key":"10.1016\/j.jhep.2021.07.029_bib131","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.jhep.2021.07.029_bib132","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib133","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib134","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2021.07.029_bib135","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2021.07.029_bib136","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib137","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2021.07.029_bib138","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"issue":"9972","key":"10.1016\/j.jhep.2021.07.029_bib139","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/cr.2010.183","article-title":"NF-kappaB and ST","volume":"21","author":"He","year":"2011","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib141","doi-asserted-by":"crossref","first-page":"17210","DOI":"10.1038\/s41598-018-35496-z","article-title":"Suppression of hepatic bile acid synthesis by a non-tumorigenic FGF19 analogue protects mice from fibrosis and hepatocarcinogenesis","volume":"8","author":"Gadaleta","year":"2018","journal-title":"Sci Rep"},{"issue":"247","key":"10.1016\/j.jhep.2021.07.029_bib142","doi-asserted-by":"crossref","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","article-title":"A\u00a0nontumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.jhep.2021.07.029_bib143","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2021.07.029_bib144","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"issue":"10126","key":"10.1016\/j.jhep.2021.07.029_bib145","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2021.07.029_bib146","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib147","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.07.029_bib148","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/hep.15.26","article-title":"Molecular classification of hepatocellular carcinoma: potential therapeutic implications","volume":"2","author":"Goossens","year":"2015","journal-title":"Hepat Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821019589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821019589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:15:08Z","timestamp":1748279708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821019589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":148,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0168827821019589"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.07.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}